Macquarie Group LTD Caladrius Biosciences, Inc. Transaction History

Macquarie Group LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.48 - $5.32 $4,524 - $6,916	-1,300 Closed	0 $0
Q4 2018 Feb 15, 2019	SELL	$3.49 - $5.77 $5,235 - $8,655	-1,500 Reduced 53.57%	1,300 $5,000
Q3 2018 Nov 15, 2018	SELL	$4.85 - $6.5 $57,923 - $77,629	-11,943 Reduced 81.01%	2,800 $17,000
Q2 2018 Aug 14, 2018	SELL	$3.8 - $8.64 $95,410 - $216,933	-25,108 Reduced 63.0%	14,743 $95,000
Q1 2018 May 11, 2018	BUY	$3.7 - $6.09 $36,855 - $60,662	9,961 Added 33.33%	39,851 $233,000
Q4 2017 Feb 15, 2018	BUY	$2.66 - $3.71 $60,621 - $84,550	22,790 Added 320.99%	29,890 $105,000
Q3 2017 Nov 08, 2017	BUY	$3.58 - $4.34 $25,418 - $30,814	7,100	7,100 $25,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.